Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Shares Outstanding (2020 - 2025)

Mirum Pharmaceuticals has reported Shares Outstanding over the past 6 years, most recently at $51.9 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $51.9 million for Q4 2025, up 7.36% from a year ago — trailing twelve months through Dec 2025 was $51.9 million (up 7.36% YoY), and the annual figure for FY2025 was $51.9 million, up 7.36%.
  • Shares Outstanding for Q4 2025 was $51.9 million at Mirum Pharmaceuticals, up from $51.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding for MIRM hit a ceiling of $51.9 million in Q4 2025 and a floor of $30.2 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $42.4 million (2023), compared with a mean of $41.1 million.
  • Biggest five-year swings in Shares Outstanding: grew 2.71% in 2021 and later increased 26.57% in 2023.
  • Mirum Pharmaceuticals' Shares Outstanding stood at $30.6 million in 2021, then grew by 20.84% to $37.0 million in 2022, then rose by 26.43% to $46.7 million in 2023, then grew by 3.46% to $48.3 million in 2024, then increased by 7.36% to $51.9 million in 2025.
  • The last three reported values for Shares Outstanding were $51.9 million (Q4 2025), $51.3 million (Q3 2025), and $50.1 million (Q2 2025) per Business Quant data.